Hecker M, Lückhoff A, Busse R
Department of Applied Physiology, University of Freiburg, Germany.
J Cell Physiol. 1993 Sep;156(3):571-8. doi: 10.1002/jcp.1041560317.
Receptor-mediated elevations of intracellular Ca2+ in endothelial cells may be controlled by a negative feedback mechanism through activation of protein kinase C (PKC). To test this hypothesis, we studied the effects of an activation or inhibition of PKC on the release of nitric oxide (NO) and prostacyclin (PGI2) from cultured bovine and porcine aortic endothelial cells (EC). Preincubation with the PKC activators phorbol-12-myristate-13-acetate (PMA) (3-300 nM) or 1-oleyl-2-acetyl-glycerol (OAG) (30 microM) significantly attenuated the release of NO and PGI2 from EC stimulated with bradykinin (0.3-30 nM), whereas phorbol-12,13-didecanoate (PDD) (30-300 nM), which does not activate PKC, had no effect. UCN-01 (10 nM), a specific PKC inhibitor, significantly augmented the bradykinin-stimulated release of NO from EC. These effects were correlated with a reduced (PMA) or enhanced (UCN-01) elevation of intracellular Ca2+ in response to bradykinin in both types of EC. Neither the PKC activators nor the inhibitor had any effect on resting intracellular Ca2+ or basal endothelial autacoid release. Several isoforms of PKC (namely PKC alpha, PKC delta, PKC epsilon, and PKC zeta) were detected in bovine, human, and porcine EC by immunoblotting analysis with isotype-specific anti-PKC antibodies, which, except PKC epsilon, were predominantly located in the cytosol. Incubation of bovine EC with PMA elicited a significant increase in membrane-bound PKC alpha immunoreactivity, whereas there was no translocation of PKC alpha from the cytosolic to the membrane fraction with bradykinin. As determined by histone phosphorylation, PKC activity was similarly reduced in the cytosol, but increased in the membrane fraction of bovine EC exposed to PMA, whereas bradykinin had no significant effect. These findings indicate that endothelial autacoid release can be modulated by activators and inhibitors of PKC. However, stimulation of EC with bradykinin does not lead to a detectable activation of PKC, suggesting that PKC does not exert a negative feedback in the signal transduction pathway of this receptor-dependent agonist.
内皮细胞中受体介导的细胞内钙离子浓度升高可能受蛋白激酶C(PKC)激活后的负反馈机制调控。为验证这一假说,我们研究了PKC激活或抑制对培养的牛和猪主动脉内皮细胞(EC)释放一氧化氮(NO)和前列环素(PGI2)的影响。用PKC激活剂佛波醇-12-肉豆蔻酸酯-13-乙酸酯(PMA)(3 - 300 nM)或1-油酰基-2-乙酰甘油(OAG)(30 μM)预孵育,可显著减弱缓激肽(0.3 - 30 nM)刺激的内皮细胞释放NO和PGI2,而不激活PKC的佛波醇-12,13-十二烷酸酯(PDD)(30 - 300 nM)则无此作用。特异性PKC抑制剂UCN - 01(10 nM)可显著增强缓激肽刺激的内皮细胞释放NO。这些效应与两种内皮细胞中缓激肽刺激后细胞内钙离子浓度升高的降低(PMA)或增强(UCN - 01)相关。PKC激活剂和抑制剂对静息细胞内钙离子浓度或基础内皮自分泌物质释放均无影响。通过免疫印迹分析,用亚型特异性抗PKC抗体在牛、人及猪内皮细胞中检测到几种PKC亚型(即PKCα、PKCδ、PKCε和PKCζ),除PKCε外,它们主要位于胞质溶胶中。用PMA孵育牛内皮细胞可使膜结合的PKCα免疫反应性显著增加,而缓激肽刺激时PKCα并未从胞质溶胶转位至膜部分。通过组蛋白磷酸化测定,牛内皮细胞暴露于PMA后,胞质溶胶中PKC活性同样降低,但膜部分活性增加,而缓激肽无显著影响。这些发现表明,PKC激活剂和抑制剂可调节内皮自分泌物质释放。然而,缓激肽刺激内皮细胞不会导致可检测到的PKC激活,提示PKC在这种受体依赖性激动剂的信号转导途径中不发挥负反馈作用。